The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT06853665
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The investigators are conducting a 10-week brain imaging and medication study. They are doing the research to study the response of Attention-Deficit/ Hyperactivity Disorder (ADHD) in youth with Autism Spectrum Disorder (ASD) on extended-release formulation of mixed amphetamine salts (MAS) (also know as Adderall XR). The investigators also want to find out if taking MAS has any effect on the brains of children and adolescents with ADHD and ASD. This study will help researchers better understand how the use of MAS to treat ADHD effects children and adolescents with ASD.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Attention Deficit Hyperactivity Disorder (ADHD)
- Autism
- Autism Spectrum Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 8 to 18 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Gagan Joshi
- Last updated on ClinicalTrials.gov
- March 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.